
-
Sol-Gel NasdaqCM:SLGL Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Location: 7 Golda Meir Street, Ness Ziona, 7403650, Israel | Website: https://www.sol-gel.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
4.378M
Cash
16.9M
Avg Qtr Burn
N/A
Short % of Float
1.86%
Insider Ownership
66.23%
Institutional Own.
24.29%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EPSOLAY® (benzoyl peroxide) Cream Details Papulopustular Rosacea | Approved Update | |
Approved Quarterly sales | ||
SGT-610 (Patidegib) Details Gorlin Syndrome, Basal cell carcinoma | Phase 3 Data readout | |
SGT-210 (Erlotinib) Details Pachyonychia congenita, Skin disease/disorder | IND Submission |